Relapsed Acute Lymphoblastic Leukemia (ALL) Recruiting Phase 2 Trials for Doxorubicin (DB00997)

Back to Relapsed Acute Lymphoblastic Leukemia (ALL)

Also known as: Acute Lymphoblastic Leukemia, in Relapse / Relapsed ALL / Relapsed Acute Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0069491 (Relapsed Acute Lymphoblastic Leukemia (ALL))	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06034561	Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia	Treatment	Bortezomib (DB00188) Dexamethasone (DB01234) Doxorubicin (DB00997) Methotrexate (DB00563) Pegaspargase (DB00059) Vincristine (DB00541)